23 June 2025NewsAmericasDavid Gindler, Orrick

WATCH: Section 112—Where has the dust settled?

David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied—and how it may continue to be applied—by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.
Americas
9 February 2026   The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.
Americas
6 February 2026   A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.